AR079231A1 - Derivados de imidazoquinolina - Google Patents
Derivados de imidazoquinolinaInfo
- Publication number
- AR079231A1 AR079231A1 ARP100104434A ARP100104434A AR079231A1 AR 079231 A1 AR079231 A1 AR 079231A1 AR P100104434 A ARP100104434 A AR P100104434A AR P100104434 A ARP100104434 A AR P100104434A AR 079231 A1 AR079231 A1 AR 079231A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- cyano
- cycloalkyl
- halogen
- Prior art date
Links
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 3
- -1 cyano, hydroxyl Chemical group 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000006595 (C1-C3) alkylsulfinyl group Chemical group 0.000 abstract 2
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 abstract 2
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 abstract 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 150000003573 thiols Chemical class 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Como procesos para su preparacion, composiciones farmacéuticas que los contienen y su uso en terapia porque tienen propiedades de inmunomoduladoras que actuan vía TLR7 que son utiles en el tratamiento de enfermedades virales, alérgicas y cáncer. Reivindicacion 1: Un compuesto de la formula (1) donde R1 representa alquilo C1-8, cicloalquilo C3-8, o un grupo anular heterocíclico saturado de 3 a 8 miembros que comprende un átomo de O, donde R1 está opcionalmente sustituido por uno o más sustituyentes seleccionados en forma independiente de halogeno, ciano, hidroxilo y alcoxi C1-3; Z1 representa un grupo alquileno C2-6, donde un átomo de carbono en Z1 que no es adyacente a un átomo de nitrogeno puede estar reemplazado con un átomo de oxígeno; X1 representa NR5, >N-COR5, >N-CONR5R5a, CONR5, NR5CO, NR5CONR6 o NR6CONR5; Y1 representa un enlace simple o alquileno C1-6; cada R2 se selecciona en forma independiente de halogeno, ciano, hidroxi, tiol, alquilo C1-3, hidroxialquilo C1-3, haloalquilo C1-3, alcoxi C1-3, haloalcoxi C1-3, alquiltio C1-3, alquilsulfonilo C1-3 y alquilsulfinilo C1-3; R3 representa alquilo C1-6 opcionalmente sustituido por alcoxi C1-6; cada Ra se selecciona en forma independiente de halogeno, ciano, hidroxi, tiol, alquilo C1-3, hidroxialquilo C1-3, haloalquilo C1-3, alcoxi C1-3, haloalcoxi C1-3, alquiltio C1-3, alquilsulfonilo C1-3 y alquilsulfinilo C1-3; R5 y R5a representan cada uno en forma independiente hidrogeno, un anillo heterocíclico saturado de 3 a 8 miembros que comprende un grupo anular O, S(O)p o NR10, un grupo alquilo C1-6 o grupo cicloalquilo C3-6, los ultimos dos grupos estando opcionalmente sustituidos por uno o más sustituyentes seleccionados en forma independiente de NR7R8 o R9, R7 y R8 representan cada uno en forma independiente hidrogeno, un anillo heterocíclico saturado de 3 a 8 miembros que comprende un grupo anular O, S(O)p o NR10a, alquilo C1-6 o cicloalquilo C3-6, los ultimos dos grupos estando opcionalmente sustituidos por uno o más sustituyentes seleccionados en forma independiente de halogeno, ciano, S(O)qR11, OR12, CO2R12, OC(O)R12, SO2NR12R13, CONR12R13, NR12R13, NR12SO2R14, NR12COR13, o un anillo heterocíclico saturado de 3 a 8 miembros que comprende un grupo anular O, S(O)p o NR10b; o R7 y R8 junto con el átomo de nitrogeno al que están unidos forman un anillo heterocíclico saturado de 3 a 8 miembros que comprende un átomo anular de nitrogeno y opcionalmente uno o más heteroátomos adicionales seleccionados en forma independiente de nitrogeno, oxígeno, azufre y sulfonilo, el anillo heterocíclico estando opcionalmente sustituido por uno o más sustituyentes seleccionados en forma independiente de halogeno, ciano, S(O)qR15, OR15, CO2R15, COR15, OC(O)R15, SO2NR15R16, CONR15R16, NR15R16, NR15SO2R17, NR15COR16, NR15CO2R16, heteroarilo, haloalquilo C1-6, cicloalquilo C3-8 y alquilo C1-6, los ultimos dos grupos estando opcionalmente sustituidos por uno o más sustituyentes seleccionados en forma independiente de ciano, S(O)qR18, OR18, CO2R18, SO2NR18R19, CONR18R19 o NR18R19; R9 representa halogeno, ciano, CO2R20, S(O)qR20, OR20, SO2NR20R22, CONR20R22, NR20SO2R21, NR20CO2R21, NR20COR22 o un anillo heterocíclico saturado de 3 a 8 miembros que comprende un grupo anular NR10c; R10, R10a, R10b y R10c representan independientemente hidrogeno, CO2R23, S(O)qR23, COR24, o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6 o cicloalquilo C3-8, donde cada uno puede estar opcionalmente sustituido por uno o más sustituyentes seleccionados en forma independiente de halogeno, ciano, OR25 o NR25R26; R6, R11, R12, R13, R15, R16, R18. R19. R20, R22, R24, R25 y R26 representan cada uno en forma independiente hidrogeno, alquilo C1-6 o cicloalquilo C3-6; R14, R17, R21 y R23 representan cada uno en forma independiente alquilo C1-6 o cicloalquilo C3-6; m, n, p y q representan cada uno en forma independiente un numero entero 0, 1 o 2; y A representa un grupo arilo C6-10 monocíclico o bicíclico o heteroarilo C5-12 monocíclico o bicíclico que contiene 1-3 heteroátomos; y Rb y Rc representan independientemente hidrogeno o alquilo C1-6, o Rb y Rc se combinan juntos para formar cicloalquilo C3-8, o una sal aceptable para uso farmacéutico del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28201709P | 2009-12-03 | 2009-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079231A1 true AR079231A1 (es) | 2012-01-04 |
Family
ID=43618056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104434A AR079231A1 (es) | 2009-12-03 | 2010-12-01 | Derivados de imidazoquinolina |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110136801A1 (es) |
| EP (1) | EP2507237A1 (es) |
| JP (1) | JP2013512859A (es) |
| AR (1) | AR079231A1 (es) |
| TW (1) | TW201130832A (es) |
| UY (1) | UY33078A (es) |
| WO (1) | WO2011068233A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI392678B (zh) | 2004-03-26 | 2013-04-11 | Dainippon Sumitomo Pharma Co | ９-取代-８-氧基腺嘌呤化合物 |
| US8138172B2 (en) * | 2006-07-05 | 2012-03-20 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of TLR7 |
| AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| AU2008247165B2 (en) * | 2007-05-08 | 2011-11-03 | Astrazeneca Ab | Imidazoquinolines with immuno-modulating properties |
| PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| UY31531A1 (es) | 2007-12-17 | 2009-08-03 | Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr) | |
| GB0908772D0 (en) * | 2009-05-21 | 2009-07-01 | Astrazeneca Ab | New salts 756 |
| CN102666541B (zh) | 2009-10-22 | 2015-11-25 | 吉里德科学公司 | 用于治疗特别是病毒感染的嘌呤或脱氮嘌呤的衍生物 |
| ES2575688T3 (es) | 2010-12-16 | 2016-06-30 | Sumitomo Dainippon Pharma Co., Ltd. | Derivado de imidazo[4,5-c]quinolin-1-ilo útil en terapia |
| JP5978226B2 (ja) | 2010-12-17 | 2016-08-24 | 大日本住友製薬株式会社 | プリン誘導体 |
| US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
| CA2850932A1 (en) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
| AU2013261267B2 (en) | 2012-05-18 | 2017-06-29 | Sumitomo Pharma Co., Ltd. | Carboxylic acid compounds |
| AR098436A1 (es) * | 2013-11-19 | 2016-05-26 | Actelion Pharmaceuticals Ltd | Compuestos tricíclicos de piperidina |
| GB201321242D0 (en) | 2013-12-02 | 2014-01-15 | Immune Targeting Systems Its Ltd | Immunogenic compound |
| PL3134402T3 (pl) | 2014-04-22 | 2020-11-02 | F.Hoffmann-La Roche Ag | Związki 4-amino-imidazochinolinowe |
| PE20171456A1 (es) | 2015-03-06 | 2017-10-06 | Hoffmann La Roche | Compuestos de dicarboxamida de benzazepinas |
| CA2980100A1 (en) * | 2015-05-04 | 2016-11-10 | Actelion Pharmaceuticals Ltd | Tricyclic piperidine compounds |
| CN108137586B (zh) * | 2015-09-14 | 2021-04-13 | 辉瑞大药厂 | 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物 |
| JP6893501B2 (ja) | 2015-09-17 | 2021-06-23 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | スルフィニルフェニル又はスルホンイミドイルフェニルベンザゼピン |
| JP6918838B2 (ja) | 2016-05-23 | 2021-08-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 第三級アミド基を有するベンズアゼピンジカルボキサミド化合物 |
| JP7022702B2 (ja) | 2016-05-23 | 2022-02-18 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 第二級アミド基を有するベンズアゼピンジカルボキサミド化合物 |
| EP3468963B1 (en) | 2016-06-12 | 2021-10-27 | F. Hoffmann-La Roche AG | Dihydropyrimidinyl benzazepine carboxamide compounds |
| EP4257198A3 (en) | 2017-08-22 | 2023-10-18 | Dynavax Technologies Corporation | Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof |
| CN108148032B (zh) * | 2018-03-01 | 2019-12-13 | 北京海步医药科技股份有限公司 | 一种3,4-二氢-2h-1-苯并吡喃-2-羧酸类化合物的制备方法及其应用 |
| BR112020026890A2 (pt) | 2018-07-03 | 2021-03-30 | Jiangsu Hengrui Medicine Co., Ltd. | Derivado de piridopirimidina, método de preparação do mesmo e uso médico do mesmo |
| AU2020223031B2 (en) | 2019-02-12 | 2024-08-29 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-TLR agonist conjugates |
| CA3132229A1 (en) * | 2019-03-07 | 2020-09-10 | BioNTech SE | Process for the preparation of a substituted imidazoquinoline |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| MX2022008286A (es) | 2020-01-02 | 2022-08-08 | Jiangsu Hengrui Medicine Co | Forma cristalina del derivado de piridopirimidina y metodo de preparacion de la misma. |
| JP2023533011A (ja) * | 2020-07-08 | 2023-08-01 | スリーエム イノベイティブ プロパティズ カンパニー | Ｎ－１分岐イミダゾキノリン、そのコンジュゲート、及び方法 |
| CN114591227A (zh) * | 2021-12-28 | 2022-06-07 | 上海冬洋生物科技有限公司 | 一种ep2受体选择性的前列腺素e2激动剂的制备方法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA848968B (en) * | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| IL78643A0 (en) * | 1985-05-02 | 1986-08-31 | Wellcome Found | Purine derivatives,their preparation and pharmaceutical compositions containing them |
| US6110923A (en) * | 1994-06-22 | 2000-08-29 | Biochem Pharma Inc. | Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity |
| HUT77436A (hu) * | 1994-10-05 | 1998-04-28 | Darwin Discovery Limited | Purin- és guaninszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| JP4471404B2 (ja) | 1996-02-13 | 2010-06-02 | アストラゼネカ ユーケイ リミテッド | Ｖｅｇｆインヒビターとしてのキナゾリン誘導体 |
| ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
| KR19990044383A (ko) * | 1996-07-03 | 1999-06-25 | 나가시마 카쭈시게, 노미야마 아키히코 | 신규 퓨린 유도체 |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| WO1998035985A1 (en) | 1997-02-12 | 1998-08-20 | The Regents Of The University Of Michigan | Protein markers for lung cancer and use thereof |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| US6329381B1 (en) * | 1997-11-28 | 2001-12-11 | Sumitomo Pharmaceuticals Company, Limited | Heterocyclic compounds |
| TW572758B (en) * | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| ATE267175T1 (de) * | 1998-08-27 | 2004-06-15 | Sumitomo Pharma | Pyrimidin derivate |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| DK1553097T3 (da) | 1999-02-10 | 2010-12-13 | Astrazeneca Ab | Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil |
| US6541485B1 (en) * | 1999-06-10 | 2003-04-01 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6331539B1 (en) * | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US6573273B1 (en) * | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
| US6756382B2 (en) * | 1999-06-10 | 2004-06-29 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| GB9924361D0 (en) * | 1999-10-14 | 1999-12-15 | Pfizer Ltd | Purine derivatives |
| PL203782B1 (pl) | 1999-11-05 | 2009-11-30 | Astrazeneca Ab | Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania |
| DE122008000002I1 (de) | 2000-02-15 | 2008-04-17 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| JP2004502766A (ja) | 2000-07-07 | 2004-01-29 | アンギオジェン・ファーマシューティカルズ・リミテッド | 血管損傷剤としてのコルヒノール誘導体 |
| US20020128264A1 (en) * | 2000-07-07 | 2002-09-12 | Taylor Eve M. | Methods for treatment of conditions affected by activity of multidrug transporters |
| US20020040032A1 (en) * | 2000-07-07 | 2002-04-04 | Glasky Michelle S. | Methods for stimulation of synthesis of synaptophysin in the central nervous system |
| CA2410562A1 (en) | 2000-07-07 | 2002-01-31 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| EP1790344B1 (en) * | 2000-07-07 | 2011-02-23 | Spectrum Pharmaceuticals, Inc. | Methods for treatment of disease-induced peripheral neuropathy and related conditions |
| WO2002040481A2 (en) * | 2000-11-20 | 2002-05-23 | Millennium Pharmaceuticals, Inc. | Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions and method of use thereof |
| ATE404561T1 (de) * | 2001-04-17 | 2008-08-15 | Dainippon Sumitomo Pharma Co | Neue adeninderivate |
| ITRM20010465A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
| US20030144711A1 (en) * | 2002-01-29 | 2003-07-31 | Neuropace, Inc. | Systems and methods for interacting with an implantable medical device |
| US20060252774A1 (en) * | 2002-05-02 | 2006-11-09 | Vatner Stephen F | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases |
| TWI349671B (en) * | 2002-09-27 | 2011-10-01 | Dainippon Sumitomo Pharma Co | Novel adenine derivative and its use |
| JP4189654B2 (ja) * | 2003-04-18 | 2008-12-03 | セイコーエプソン株式会社 | 画像処理装置 |
| EA200600069A1 (ru) * | 2003-06-20 | 2006-08-25 | Коли Фармасьютикал Гмбх | Низкомолекулярные антагонисты toll-подобных рецепторов (tlr) |
| ES2342069T4 (es) * | 2003-09-05 | 2011-01-26 | Anadys Pharmaceuticals, Inc. | Ligandos de tlr7 para el tratamiento de la hepatitis c. |
| CA2545825A1 (en) * | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
| TWI392678B (zh) * | 2004-03-26 | 2013-04-11 | Dainippon Sumitomo Pharma Co | ９-取代-８-氧基腺嘌呤化合物 |
| JPWO2005092892A1 (ja) * | 2004-03-26 | 2008-02-14 | 大日本住友製薬株式会社 | ８−オキソアデニン化合物 |
| EP1888587A1 (en) * | 2005-05-04 | 2008-02-20 | Pfizer Limited | 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c |
| CA2620182A1 (en) * | 2005-08-22 | 2007-03-01 | Dennis A. Carson | Tlr agonists |
| TW200801003A (en) * | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| JPWO2007034817A1 (ja) * | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
| EP1939201A4 (en) * | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
| WO2007034881A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
| TW200745114A (en) * | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| JPWO2007034882A1 (ja) * | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
| EP1939200A4 (en) * | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
| US20090281075A1 (en) * | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| US8138172B2 (en) * | 2006-07-05 | 2012-03-20 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of TLR7 |
| ES2437871T3 (es) * | 2006-07-07 | 2014-01-14 | Gilead Sciences, Inc. | Moduladores del receptor tipo toll 7 |
| TW200831105A (en) * | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| US20100120799A1 (en) * | 2007-02-19 | 2010-05-13 | Smithkline Beecham Corporation | Purine derivatives as immunomodulators |
| EP2139894B1 (en) * | 2007-03-19 | 2011-10-26 | AstraZeneca AB | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators |
| JP5480637B2 (ja) * | 2007-03-19 | 2014-04-23 | アストラゼネカ・アクチエボラーグ | Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物 |
| AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| US8044056B2 (en) * | 2007-03-20 | 2011-10-25 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound |
| AU2008247165B2 (en) * | 2007-05-08 | 2011-11-03 | Astrazeneca Ab | Imidazoquinolines with immuno-modulating properties |
| JP5395068B2 (ja) * | 2007-06-29 | 2014-01-22 | ギリアード サイエンシーズ， インコーポレイテッド | トール様受容体７の調節物質としてのプリン誘導体およびその使用 |
| PE20091236A1 (es) * | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| CA2711769A1 (en) * | 2008-01-17 | 2009-07-23 | Dainippon Sumitomo Pharma Co. Ltd. | Method for preparing adenine compound |
| WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| UA103195C2 (uk) * | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| JP2010062846A (ja) * | 2008-09-03 | 2010-03-18 | Ntt Docomo Inc | 無線通信制御方法、無線通信基地局、無線通信端末および無線通信システム |
| GB0908772D0 (en) * | 2009-05-21 | 2009-07-01 | Astrazeneca Ab | New salts 756 |
-
2010
- 2010-11-30 EP EP10788414A patent/EP2507237A1/en not_active Withdrawn
- 2010-11-30 WO PCT/JP2010/071773 patent/WO2011068233A1/en not_active Ceased
- 2010-11-30 JP JP2012525776A patent/JP2013512859A/ja active Pending
- 2010-12-01 AR ARP100104434A patent/AR079231A1/es unknown
- 2010-12-02 TW TW099141932A patent/TW201130832A/zh unknown
- 2010-12-02 US US12/958,846 patent/US20110136801A1/en not_active Abandoned
- 2010-12-03 UY UY0001033078A patent/UY33078A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110136801A1 (en) | 2011-06-09 |
| JP2013512859A (ja) | 2013-04-18 |
| TW201130832A (en) | 2011-09-16 |
| WO2011068233A1 (en) | 2011-06-09 |
| EP2507237A1 (en) | 2012-10-10 |
| UY33078A (es) | 2011-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079231A1 (es) | Derivados de imidazoquinolina | |
| AR066492A1 (es) | Derivados de imidazoquinolina, proceso para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de enfermedades virales, bacterianas, alergicas y distintos tipos de canceres. | |
| AR078168A1 (es) | Derivados de piperidinas y piperazinas, procesos para prepararlos y sus usos como moduladores de gpr119 | |
| AR077505A1 (es) | Compuestos de piridina y sus usos | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| NO20073729L (no) | Heterocykliske forbindelser som CCR2B-antagonister | |
| AR078635A1 (es) | Compuestos de pirrolo[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la elaboracion de un medicamento para el tratamiento de enfermedades mediadas por la quinasa de janus | |
| PE20090183A1 (es) | Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5 | |
| PE20141205A1 (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2 | |
| AR078786A1 (es) | Derivados de la cromenona | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
| RU2014129742A (ru) | Производные бензолсульфонамида в качестве модуляторов rorc | |
| PE20171177A1 (es) | Compuestos aminopirimidinilo inhibidores de jak | |
| AR079224A1 (es) | Compuestos insecticidas basados en derivados de isoxazolina | |
| AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
| PE20140011A1 (es) | Compuestos y composiciones novedosos para la inhibicion de nampt | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| PE20142456A1 (es) | COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR060658A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| JP2016505536A5 (es) | ||
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |